Celyad VP talks IP issues, development timelines for CAR-T therapies

Georges Rawadi, VP of business development and intellectual property at Celyad, discusses the company's CAR-T pipeline, recently resolved IP issues and the firm's strategy for future clinical development. At the recent BIO-Europe Spring partnering meeting in Barcelona, Rawadi told Scrip more about how Celyad's technology will compete with other treatments coming through the immuno-oncology development pipeline and the next big milestones for the business.

Interviewer: Lucie Ellis – Senior Writer, Pharma Intelligence In Vivo/Pink Sheet/Scrip
Interviewee: Georges Rawadi – VP Business Development and IP, Celyad